Procter & Gamble Health Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 45 per equity share.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 10.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Limited reported audited financial results for the Financial Year ended March 31, 2026. Revenue from operations stood at Rs. 1,40,797 lakhs, with Net Profit at Rs. 32,691 lakhs — up from Rs. 23,441 lakhs in the prior 9-month period (FY was changed from June to March year-end). EPS for the year is Rs. 196.94. The Board recommended a final dividend of Rs. 45 per share (total outflow Rs. 7,470 lakhs), bringing total dividend for the year to Rs. 205 per share (including Rs. 160 interim dividend and special dividend already paid). The statutory auditors, Haribhakti & Co. LLP, issued an unmodified opinion. Operating cash flow for the year was Rs. 33,779 lakhs.
Strong financial performance with ~40% profit growth and robust cash generation supports the generous dividend payout. The stock remains attractive for income-focused investors.